The European Commission (EC) has granted marketing authorization for Sandoz’s Wyost (denosumab) and Jubbonti (denosumab), the first and only biosimilar versions of reference medicines Xgeva and Prolia in Europe.
 
Wyost is approved for the treatment of cancer-related bone disease, while Jubbonti is approved to treat osteoporosis. These are key biosimilar value drivers for the company over the mid-term and their approval is a major step in advancing the Sandoz growth strategy. The biosimilars are expected to launch in late 2025.
 
Claire D’Abreu-Hayling, Sandoz Chief Scientific Officer, said: “Primary and secondary bone loss, as well as cancer-related bone events, represent an immense disease burden for patients, the economy and society as a whole. The approval of the first European denosumab biosimilars is a crucial recognition of the need for increased access to these potentially life-changing medicines and demonstrates our continued commitment to delivering more sustainable treatment options for patients, in Europe and beyond.”